Clinical Trial

Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

Study acronym: LSD-LPPH
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.
Trial Details
NCT Number NCT07588334
Lead Sponsor Northern Jiangsu People's Hospital
Conditions Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension, Lipid Profiles
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2029-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-14